Overview

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function
Phase:
Phase 1
Details
Lead Sponsor:
Acorda Therapeutics
Treatments:
4-Aminopyridine